New ready-to-use cartridge, Schott Pharma targets growing wearable injector market

Schott Pharma is expanding its ready-to-use portfolio with a new small-volume sterile cartridge designed for wearable and on-body injectors, aiming at biotech and pharma customers developing high-value biologics and chronic therapies.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 10:05 PM ET. Details in the imprint.

Schott Pharma is sharpening its focus on advanced drug delivery with a new small-volume ready-to-use cartridge aimed at wearable and on-body injectors in human use. The sterile glass container is delivered pre-washed, sterilized and packed for direct filling, targeting biotech and pharma companies working on self-administration therapies for chronic diseases and high-value biologics.

What Schott Pharma’s new RTU cartridge is designed to do

According to Schott Pharma, the new small-volume ready-to-use cartridge expands its existing RTU portfolio and is specifically optimized for human use applications such as insulin, GLP-1 agonists and other subcutaneous biologics that are increasingly administered via wearable or on-body injector systems rather than traditional syringes. The company positions the container as part of its broader strategy to offer pre-validated delivery components that help customers shorten development timelines and reduce complexity in fill-finish operations; the cartridge is supplied in standardized tub and nest formats compatible with modern aseptic filling lines, helping device and pharma partners integrate it into existing infrastructure with fewer custom adjustments as highlighted by Manufacturing Chemist’s coverage of the launch.

The cartridge is manufactured in pharmaceutical-grade glass and undergoes a process chain of washing, depyrogenation and sterilization before being sealed and shipped, which is intended to give drug makers a container that can go directly into aseptic filling without additional in-house preparation steps. Schott Pharma underscores that this approach can cut process steps for customers, potentially lowering contamination risk and freeing capacity in constrained cleanroom environments. For sensitive biologics and high-cost therapies, reducing the risk of particulates and endotoxins in primary packaging is a key selling point, and RTU formats are increasingly seen as a way to standardize quality across global production sites.

In addition to the new cartridge, Schott Pharma has recently emphasized its development of polymer-based solutions for ultra-low temperature storage, pointing to its SCHOTT TOPPAC freeze prefillable polymer syringes that can withstand down to -180 °C for deep cold chain applications. While the materials and use cases differ, both offerings target the same customer need: reliable containment and delivery for complex, temperature-sensitive drugs. This aligns the new RTU cartridge with a portfolio strategy in which the company seeks to serve both conventional room-temperature biologics and emerging cell and gene therapies that demand more specialized packaging concepts as described in an earlier Manufacturing Chemist report on the ultra-low temperature syringe line.

For wearable injector and on-body device manufacturers, a pre-validated small-volume cartridge from a global supplier can simplify device qualification by using a container with known material behavior, tight dimensional tolerances and established regulatory documentation. Schott Pharma frames the cartridge as part of a platform that can support custom device designs, offering options around volume, flange geometry and closure systems to match different injection profiles and mechanical drive systems. The focus on “small-volume” is particularly relevant for potent biologics, where required doses are often delivered in a few milliliters, making precise container geometry and reliable plunger movement critical for dosing accuracy and patient safety. By targeting this segment, Schott Pharma is positioning the cartridge as a building block for next-generation self-injection ecosystems rather than a generic commodity vial.

The broader healthcare packaging market in Europe is expected to grow steadily over the next decade, with analysts citing increased demand for advanced drug delivery systems and specialized packaging for biologics as important drivers. Recent estimates point to the European healthcare packaging market rising from around $31.7 billion in the mid-2020s to over $49 billion by the mid-2030s, implying annual growth in the mid-single digits and a premium segment for high-performance primary containers that can support more complex therapies and home-based care models. This macro backdrop supports Schott Pharma’s push into RTU cartridges for wearable injectors, as drug makers search for components that can be integrated into autoinjectors, patch pumps and other devices that shift administration away from clinics toward patient homes according to growth projections for the European healthcare packaging market.

Schott Pharma, spun off from the Schott glass group and listed in Frankfurt, reports that a significant portion of its revenue comes from containment and delivery solutions for injectables, including vials, syringes and cartridges. The new small-volume ready-to-use cartridge is meant to broaden that base by tapping into wearable injector and on-body device projects that are moving from development into commercial deployment, particularly in diabetes, obesity and autoimmune indications. Shares of Schott Pharma (DE000A3ENQ51) most recently traded on Xetra in Frankfurt at around €17.62 in mid-June 2026, reflecting investor expectations that demand for advanced drug containers and delivery systems will continue to grow alongside the market for biologic therapies.

Schott Pharma RTU cartridge in brief: the key data

• Product: Small-volume ready-to-use cartridge for human use
• Manufacturer: Schott Pharma KGaA
• Category: New Release - ready-to-use primary packaging for injectables
• Launch date: 2026 (announced as portfolio expansion)
• MSRP / Price: Not publicly disclosed; priced for B2B pharma and biotech customers
• Availability: Offered to global pharmaceutical and biotech clients as part of Schott Pharma’s RTU portfolio
• Target audience: Pharmaceutical and biotechnology companies developing injectable biologics for wearable and on-body injectors, particularly in chronic disease and self-administration segments
• Key differentiator / USP: Sterile small-volume glass cartridge supplied in ready-to-use tub and nest format for direct integration into modern aseptic filling lines and wearable injector systems

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.